After tirzepatide was approved for marketing in the United States in 2022, the number of prescriptions has continued to grow rapidly, and the growth rate far exceeds that of semaglutide during the same period, driving the rapid increase of tirzepatide's market share
Most important she knows her stuff
Both medications are administered via a once-weekly injection and can be adjusted over time based on how your body responds
It requires prompt medical attention and can range from mild, self-limiting episodes to severe, life-threatening complications
Then you can read through the rest of the guide to understand how we made our selections
Insurance coverage for GLP-1 medications like Ozempic has become increasingly restrictive, with most major carriers including Aetna limiting approval to patients with diagnosed type 2 diabetes rather than obesity alone